UPTRAVI Film-coated tablet (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Uptravi 200 microgram film-coated tablets. Uptravi 400 microgram film-coated tablets. Uptravi 600 microgram film-coated tablets. Uptravi 800 microgram film-coated tablets. Uptravi 1,000 microgram film-coated ...
Qualitative and quantitative composition
<u>Uptravi 200 microgram film-coated tablets:</u> Each film-coated tablet contains 200 micrograms of selexipag. <u>Uptravi 400 microgram film-coated tablets:</u> Each film-coated tablet contains 400 micrograms ...
Pharmaceutical form
Film-coated tablet. <u>Uptravi 200 microgram film-coated tablets:</u> Round, light-yellow, film-coated tablets with 2 debossed on one side. <u>Uptravi 400 microgram film-coated tablets:</u> Round, red, ...
Therapeutic indications
Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently ...
Posology and method of administration
Treatment should only be initiated and monitored by a physician experienced in the treatment of PAH. Posology Individualised dose titration Each patient should be up-titrated to the highest individually ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Severe coronary heart disease or unstable angina. Myocardial infarction within the last 6 months. Decompensated ...
Special warnings and precautions for use
Hypotension Uptravi has vasodilatory properties that may result in lowering of blood pressure. Before prescribing Uptravi, physicians should carefully consider whether patients with certain underlying ...
Interaction with other medicinal products and other forms of interaction
Effect of other medicinal products on selexipag Selexipag is hydrolysed to its active metabolite by carboxylesterases (see section 5.2). Selexipag and its active metabolite both undergo oxidative metabolism ...
Fertility, pregnancy and lactation
Women of childbearing potential Women of childbearing potential should practise effective contraception while taking selexipag. Pregnancy There are no data from the use of selexipag in pregnant women. ...
Effects on ability to drive and use machines
Uptravi has minor influence on the ability to drive and use machines. The clinical status of the patient and the adverse reaction profile of selexipag (such as headache or hypotension) should be kept in ...
Undesirable effects
Summary of the safety profile The most commonly reported adverse reactions are headache, diarrhoea, nausea and vomiting, jaw pain, myalgia, pain in extremity, arthralgia, and flushing. These reactions ...
Overdose
Isolated cases of overdose up to 3,200 micrograms were reported. Mild, transient nausea was the only reported consequence. In the event of overdose, supportive measures must be taken as required. Dialysis ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excluding heparin ATC code: B01AC27 Mechanism of action Selexipag is a selective IP receptor agonist distinct from prostacyclin ...
Pharmacokinetic properties
The pharmacokinetics of selexipag and its active metabolite have been studied primarily in healthy subjects. The pharmacokinetics of selexipag and the active metabolite, both after single- and multiple-dose ...
Preclinical safety data
In the repeated-dose toxicity studies in rodents, strong blood pressure decrease as a result of exaggerated pharmacology induced transient clinical signs and reduced food consumption and body-weight gain. ...
List of excipients
<u>Tablet core:</u> Mannitol (E421) Maize starch Low substituted hydroxypropyl cellulose Hydroxypropyl cellulose Magnesium stearate <u>Film coating:</u> Uptravi 200 microgram film-coated tablet: Hypromellose ...
Incompatibilities
Not applicable.
Shelf life
3 years.
Special precautions for storage
This medicinal product does not require any special storage conditions.
Nature and contents of container
Polyamide/aluminium/HDPE/PE with an embedded desiccant agent/HDPE blister sealed with an aluminium foil. Uptravi 200 microgram film-coated tablets: Cartons of 10 or 60 film-coated tablets, and 60 or 140 ...
Special precautions for disposal and other handling
No special requirements for disposal.
Marketing authorization holder
Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium
Marketing authorization number(s)
EU/1/15/1083/001 EU/1/15/1083/002 EU/1/15/1083/003 EU/1/15/1083/004 EU/1/15/1083/005 EU/1/15/1083/006 EU/1/15/1083/007 EU/1/15/1083/008 EU/1/15/1083/009 EU/1/15/1083/010 EU/1/15/1083/011
Date of first authorization / renewal of the authorization
Date of first authorisation: 12 May 2016
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: